What Will Work in the World as It Is?
83
almost every aspect of Biogen Idec’s business. In principle,
the FDA was a neutral, independent, science-based arbiter of
drug safety. In reality, it was also a player in a very complex,
high-stakes financial and political contest. The FDA had
vigorous, well-organized adversaries. Some critics believed it
moved too slowly on promising new drugs. Others believed
it was the captive of large pharmaceutical companies. At the
time of the Tysabri controversy, the FDA was reeling from
its recent approval and embarrassing withdrawal of Vioxx,
a treatment for acute pain, that caused hundreds of deaths
and serious cardiac problems, and the agency badly needed
to restore its credibility.
In addition, Mullen knew that the FDA would soon be
besieged by MS patients, their families, legislators, physicians,
and others who wanted Tysabri to remain available, and these
groups would be able to make powerful, heart-wrenching
cases because MS sufferers urgently needed better treatments.
Investors, competitors, key employees, and other groups also
had strong interests in whatever Mullen did, so he would be
making moves on a very complicated chessboard.
In situations like this, understanding power sometimes
means looking accurately at the brute force—the “hard”
power—that you and other parties can use. In Friedman’s
case, she believed that her bosses could fire her or force her
out of the company. In Mullen’s case, hard power consisted of
the many ways a regulator like the FDA could make life mis-
erable for a company.
18
In most cases, however, sophisticated
parties rely heavily on “soft” power. They operate subtly and
obliquely. Instead of threatening, they nudge and entice. They
Chapter_04.indd 83 10/06/16 11:15 PM